Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Are peptides legal in North Dakota?

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Yes. A North Dakota resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a North Dakota-licensed prescriber, including by telemedicine under NDCC 43-17-44, which requires a bona fide relationship, identity verification, and the same standard of care as in-person practice. The statute lets the examination be done entirely by telemedicine if it is equivalent to an in-person examination. It says an examination using secure videoconferencing or store-and-forward technology for appropriate diagnostic testing and use of peripherals that a like in-person examination would need meets that standard, but a static online questionnaire or an audio conversation alone does not. NDCC 43-17-45 then permits a licensee who has performed a qualifying telemedicine examination to prescribe. A compounded peptide is available when it is eligible under federal 503A rules and dispensed by a pharmacy holding a North Dakota State Board of Pharmacy permit. North Dakota is unusual in two ways: every out-of-state pharmacy shipping prescriptions into the state must hold a full North Dakota pharmacy permit, and in-state pharmacies must be majority owned by pharmacists under NDCC 43-15-35.

Regulatory: Telehealth allowedRegulatory: Async allowedRegulatory: Compounded GLP-1 limitedVerified: Verified Oct 28, 2026
Compounding rules
Follows the federal 503A framework
Telehealth prescribing
Allowed, asynchronous allowed; a questionnaire alone is not enough
Compounded GLP-1
Limited

Can a North Dakota resident get peptides by telehealth?

NDCC 43-17-44 holds a physician or physician assistant to the same standard of care in telemedicine as in person and requires a bona fide relationship, identity verification, and an examination or evaluation before first diagnosing or treating a patient. The examination may be performed entirely through telemedicine if it is equivalent to an in-person examination. The statute says an examination using secure videoconferencing or store-and-forward technology for appropriate diagnostic testing and use of peripherals that an in-person examination would need meets that standard, while one consisting only of a static online questionnaire or an audio conversation does not. NDCC 43-17-45 then lets a licensee who has performed a qualifying telemedicine examination prescribe according to professional judgment, with opioids restricted. The Board of Medicine's rules in NDAC chapter 50-02-15 repeat the definition of telemedicine, which includes asynchronous store-and-forward technologies. The prescriber must hold a North Dakota license unless a narrow exception applies. None of the peptides in this database are controlled substances. This record classifies asynchronous prescribing as allowed because the statute names store-and-forward technology, alongside secure videoconferencing, as an acceptable way to perform the required examination and then permits prescribing, while barring a static online questionnaire alone. [2] [3]

How does the North Dakota pharmacy board treat compounding?

Compounding regulator for North Dakota
BoardNorth Dakota State Board of Pharmacy
Eligible substancesFollows the federal 503A framework

The North Dakota State Board of Pharmacy licenses pharmacists and permits pharmacies under NDCC chapter 43-15 and adopts rules in NDAC Title 61. Under NDAC chapter 61-08-01, any pharmacy that ships, mails, or delivers prescription drugs into North Dakota must obtain and hold a North Dakota pharmacy permit and follow North Dakota law for the part of its operation that dispenses to North Dakota residents; permits are renewed each year by July 1. NDCC 43-15-35 requires in-state pharmacies to be majority owned by North Dakota-licensed pharmacists, a rule upheld by the U.S. Supreme Court in North Dakota State Board of Pharmacy v. Snyder's Drug Stores (1973). Compounding standards are in NDAC chapter 61-02-01 (pharmacy permits): section 61-02-01-03 requires nonsterile compounding to meet USP chapter 795 and sterile preparations to be compounded, and sterile compounding facilities and equipment to conform, according to USP chapter 797, with hazardous drugs handled under USP chapter 800, and the chapter issues a separate Class C permit to pharmacies that dispense sterile injectable products to the general public. North Dakota has no state bulks list; peptide eligibility follows the federal 503A framework. [1] [4] [5] [6] [8]

Can you get compounded GLP-1s in North Dakota?

Regulatory: Compounded GLP-1 limited

Because North Dakota requires a full pharmacy permit for every out-of-state shipper, fewer national telehealth pharmacies serve the state, and patients should confirm the pharmacy's North Dakota permit before ordering. [4] [11]

Prices by channel: semaglutide cost, tirzepatide cost.

Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.

What is the legal access path in North Dakota?

Access options

We may earn a commission from these links.

Prices are the partner's own and are not verified by PeptideAgent. You answer health questions after checkout, and the partner's clinician decides whether to prescribe.

Unsponsored access paths are checked against public regulatory records. Sponsored offers are the partner's and are labeled. Products labeled research use only are never listed.

Find a provider in North Dakota

What you'll actually find in North Dakota, and how to check

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [15] [16] [17]

No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [18]

What North Dakota has done

PeptideAgent has not found a board or legislative action on peptides in North Dakota.

Other states have acted:

  • On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [20] Mississippi law
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [21] [22] Louisiana law

Checking the prescriber

Telehealth prescribing of non-controlled peptides is permitted in North Dakota. A prescriber may prescribe without a live visit (asynchronous care) when it meets the standard of care. State law says an online questionnaire alone is not enough. [2] [3] The telehealth rule in full.

Checking the pharmacy

Look the pharmacy up yourself before you pay, including an out-of-state mail-order pharmacy. The pharmacy regulator is the North Dakota State Board of Pharmacy; its license search: FDA BeSafeRx: state board of pharmacy license lookups. [19]

If you're going ahead anyway

These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [18]

They do not change a peptide's legal status either. That depends on the peptide: for a withdrawn nomination such as BPC-157 or TB-500, a 503A pharmacy has no federal basis to compound it from bulk, with or without a prescription, while a few Category 1 substances, such as NAD+ and glutathione, are compounded under FDA's interim policy, with conditions. Each peptide page gives its status. [9] [23] [24]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [19] [25] [26]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [17] [26] [27]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [18] [28] [29] [30] [31] [32]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [18]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [19]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [17]
  • Pharmacy: Is this made for me on a prescription written in my name? [27]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [17] [26]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [17]

What is offered for a specific peptide, and what FDA found, is on each peptide page.

Is it legal to buy research peptides in North Dakota?

The North Dakota Food, Drug, and Cosmetic Act (NDCC chapter 19-02.1) prohibits selling adulterated or misbranded drugs, and NDCC chapter 43-15 limits dispensing of prescription drugs to permitted pharmacies and licensed practitioners. [6] [7] [12]

Peptide-specific notes for North Dakota

Peptide-specific notes for North Dakota
PeptideNote
SemaglutideAvailable branded by prescription, including by telemedicine from a North Dakota-licensed prescriber who has established a bona fide relationship under NDCC 43-17-44. Compounded semaglutide is limited to the federal patient specific exception since April 22, 2025. [2] [11]

Frequently asked questions

Can I get a GLP-1 prescription in North Dakota through telemedicine?

Yes, from a North Dakota-licensed prescriber who establishes a bona fide relationship, verifies your identity, and meets the in-person standard of care under NDCC 43-17-44. NDCC 43-17-45 then permits a licensee who has performed a qualifying telemedicine examination to prescribe. Semaglutide and tirzepatide are not controlled substances. The examination can be done entirely by telemedicine, but a static online questionnaire or an audio conversation alone does not meet the standard of care. [2]

Can an out-of-state pharmacy ship compounded peptides to me in North Dakota?

Only if it holds a North Dakota pharmacy permit issued by the State Board of Pharmacy. North Dakota requires every pharmacy that ships prescription drugs into the state to hold a permit and follow North Dakota rules for that dispensing. [1] [4]

Why are most North Dakota pharmacies independently owned?

NDCC 43-15-35 requires in-state pharmacies to be majority owned by North Dakota-licensed pharmacists. The U.S. Supreme Court upheld the law in 1973, and it continues to limit chain pharmacy ownership in the state. [6]

Can a North Dakota pharmacy compound BPC-157?

Only under a draft federal policy, and only within strict limits. On October 28, 2026 HHS released a draft enforcement discretion policy saying it will not take enforcement action against a state-licensed pharmacy that compounds BPC-157 as a single-ingredient product by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. BPC-157 is still not FDA approved or on the 503A bulks list, the policy is not binding and HHS may revisit it, and blends such as Wolverine are not covered. FDA's drug center recommended against listing BPC-157; the advisory committee voted in favor (HHS policy, Appendix B). State law still applies: North Dakota has no state bulks list; peptide eligibility follows the federal 503A framework. [8] [9] [10] [13] [14]

Sources

Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, federal FDA guidance, and the FDA warning letters and studies behind what is offered.

  1. [1]North Dakota State Board of Pharmacy
  2. [2]NDCC 43-17-44, Standard of care and professional ethics, and 43-17-45 (in chapter 43-17, Physicians and physician assistants)
  3. [3]NDAC chapter 50-02-15, Telemedicine (North Dakota Board of Medicine)
  4. [4]NDAC chapter 61-08-01, Requirements for out-of-state pharmacies
  5. [5]NDAC chapter 61-02-01, Pharmacy permits (section 61-02-01-03, pharmaceutical compounding standards)
  6. [6]NDCC chapter 43-15, Pharmacy (including 43-15-35, pharmacist ownership)
  7. [7]NDCC chapter 19-02.1, Food, Drug, and Cosmetic Act
  8. [8]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  9. [9]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
  10. [10]FDA: Pharmacy Compounding Advisory CommitteeFDA

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). Are peptides legal in North Dakota?. https://peptideagent.ai/legal/north-dakota
HTML link
<a href="https://peptideagent.ai/legal/north-dakota">Are peptides legal in North Dakota?</a>, PeptideAgent, updated October 28, 2026.